MINDBIO THERAPEUTICS BEGINS DOSING MB22001 IN PHASE 2 CLINICAL TRIAL IN WORLD FIRST TAKE-HOME MICRODOSING STUDY IN PATIENTS WITH DEPRESSION World-first take-home approvals...
MINDBIO THERAPEUTICS BREAKTHROUGH DISCOVERY IN MICRODOSING CLINICAL TRIAL REVEALS SIGNIFICANT POSITIVE EFFECTS ON QUALITY OF SLEEPNew Discovery: MindBio's LSD-Microdosing Treatment Improves...
MINDBIO THERAPEUTICS CEO DEMONSTRATES HOW 1 MILLION MICRODOSES OF LSD CAN POTENTIALLY BE USED TO TREAT DEPRESSION 1 Million Microdoses used to create proprietary microdosing...
ETHICS APPROVAL FOR LANDMARK WORLD FIRST PHASE 2 CLINICAL TRIAL OF TAKE-HOME LSD-MICRODOSING FOR MAJOR DEPRESSIVE DISORDEREthics approval received for take-home LSD-Microdosing clinical...
PHASE 2 CLINICAL TRIAL HAS RECEIVED ETHICS APPROVAL FOR WORLD FIRST TAKE-HOME LSD-MICRODOSING TRIALS IN CANCER PATIENTS EXPERIENCING EMOTIONAL DISTRESSEthics approval granted The clinical trial...
MindBio Therapeutics Corp (CSE: MBIO) Reveals Scientific Paper in World-First Take-Home, LSD-Microdosing Clinical Trial in 80 Healthy Participants MindBio clinical trial...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.005 | 25 | 0.02 | 0.025 | 0.02 | 173487 | 0.02014977 | CS |
4 | -0.005 | -16.6666666667 | 0.03 | 0.035 | 0.02 | 184273 | 0.02460497 | CS |
12 | -0.01 | -28.5714285714 | 0.035 | 0.035 | 0.02 | 82714 | 0.02554565 | CS |
26 | -0.025 | -50 | 0.05 | 0.055 | 0.02 | 61658 | 0.03031425 | CS |
52 | 0 | 0 | 0.025 | 0.085 | 0.015 | 56671 | 0.03887531 | CS |
156 | -0.535 | -95.5357142857 | 0.56 | 0.56 | 0.015 | 66866 | 0.05841835 | CS |
260 | -0.535 | -95.5357142857 | 0.56 | 0.56 | 0.015 | 66866 | 0.05841835 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관